Exact Sciences Corporation Company Profile (NASDAQ:EXAS)

About Exact Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXAS
  • CUSIP: 30063P10
  • Web: www.exactsciences.com
Capitalization:
  • Market Cap: $5.64636 billion
  • Outstanding Shares: 119,096,000
Average Prices:
  • 50 Day Moving Avg: $44.75
  • 200 Day Moving Avg: $36.31
  • 52 Week Range: $13.05 - $50.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -58.99
  • P/E Growth: -1.79
Sales & Book Value:
  • Annual Revenue: $169.37 million
  • Price / Sales: 33.18
  • Book Value: $4.54 per share
  • Price / Book: 10.39
Profitability:
  • EBITDA: ($129,740,000.00)
  • Net Margins: -83.08%
  • Return on Equity: -36.36%
  • Return on Assets: -32.85%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 16.82%
  • Quick Ratio: 16.42%
Misc:
  • Average Volume: 1.66 million shs.
  • Beta: 0.75
  • Short Ratio: 7.98
 

Frequently Asked Questions for Exact Sciences Corporation (NASDAQ:EXAS)

What is Exact Sciences Corporation's stock symbol?

Exact Sciences Corporation trades on the NASDAQ under the ticker symbol "EXAS."

How were Exact Sciences Corporation's earnings last quarter?

Exact Sciences Corporation (NASDAQ:EXAS) announced its quarterly earnings data on Tuesday, July, 25th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. View Exact Sciences Corporation's Earnings History.

When will Exact Sciences Corporation make its next earnings announcement?

Exact Sciences Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Exact Sciences Corporation.

Where is Exact Sciences Corporation's stock going? Where will Exact Sciences Corporation's stock price be in 2017?

13 analysts have issued 1 year price targets for Exact Sciences Corporation's stock. Their predictions range from $28.00 to $60.00. On average, they expect Exact Sciences Corporation's stock price to reach $43.54 in the next year. View Analyst Ratings for Exact Sciences Corporation.

What are analysts saying about Exact Sciences Corporation stock?

Here are some recent quotes from research analysts about Exact Sciences Corporation stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (9/26/2017)
  • 2. Cowen and Company analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Are investors shorting Exact Sciences Corporation?

Exact Sciences Corporation saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 16,290,094 shares, a drop of 11.3% from the August 31st total of 18,365,552 shares. Based on an average daily trading volume, of 1,406,353 shares, the days-to-cover ratio is currently 11.6 days. Approximately 14.0% of the shares of the stock are sold short.

Who are some of Exact Sciences Corporation's key competitors?

Who are Exact Sciences Corporation's key executives?

Exact Sciences Corporation's management team includes the folowing people:

  • Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer
  • Jeffrey Thomas Elliott, Chief Financial Officer
  • Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director
  • Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer
  • D. Scott Coward, Senior Vice President, General Counsel, Secretary
  • David A. Thompson, Lead Independent Director
  • Thomas D. Carey, Independent Director
  • James E. Doyle, Independent Director
  • John A. Fallon M.D., Independent Director
  • Daniel J. Levangie, Independent Director

Who owns Exact Sciences Corporation stock?

Exact Sciences Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.00%). Company insiders that own Exact Sciences Corporation stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for Exact Sciences Corporation.

Who sold Exact Sciences Corporation stock? Who is selling Exact Sciences Corporation stock?

Exact Sciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold Exact Sciences Corporation stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for Exact Sciences Corporation.

How do I buy Exact Sciences Corporation stock?

Shares of Exact Sciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exact Sciences Corporation's stock price today?

One share of Exact Sciences Corporation stock can currently be purchased for approximately $47.19.


MarketBeat Community Rating for Exact Sciences Corporation (NASDAQ EXAS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  508 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  793
MarketBeat's community ratings are surveys of what our community members think about Exact Sciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exact Sciences Corporation (NASDAQ:EXAS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $43.54 (7.74% downside)
Consensus Price Target History for Exact Sciences Corporation (NASDAQ:EXAS)
Price Target History for Exact Sciences Corporation (NASDAQ:EXAS)
Analysts' Ratings History for Exact Sciences Corporation (NASDAQ:EXAS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Robert W. BairdReiterated RatingBuy$49.00N/AView Rating Details
10/3/2017Canaccord GenuityReiterated RatingBuy -> Buy$45.00 -> $60.00HighView Rating Details
9/21/2017Leerink SwannReiterated RatingOutperform -> Outperform$45.00 -> $50.00HighView Rating Details
7/26/2017Bank of America CorporationReiterated RatingBuyHighView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Craig HallumReiterated RatingBuy$41.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$35.00 -> $45.00LowView Rating Details
7/7/2017Benchmark Co.Set Price TargetBuy$50.00LowView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
6/1/2017Jefferies Group LLCSet Price TargetBuy$35.00MediumView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$45.00HighView Rating Details
5/1/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$21.00 -> $33.00MediumView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$29.00N/AView Rating Details
10/30/2015WedbushLower Price Target$7.00 -> $6.50N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)
Earnings by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Earnings History by Quarter for Exact Sciences Corporation (NASDAQ EXAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017($0.31)N/AView Earnings Details
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exact Sciences Corporation (NASDAQ:EXAS)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.40)($0.42)
Q2 20174($0.41)($0.33)($0.38)
Q3 20175($0.35)($0.28)($0.33)
Q4 20175($0.36)($0.30)($0.34)
Q1 20183($0.33)($0.29)($0.32)
Q2 20183($0.33)($0.25)($0.28)
Q3 20183($0.32)($0.21)($0.25)
Q4 20183($0.31)($0.14)($0.22)
Q1 20191($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exact Sciences Corporation (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exact Sciences Corporation (NASDAQ:EXAS)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 85.23%
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017D Scott CowardSVPSell29,115$47.16$1,373,063.40View SEC Filing  
10/2/2017Graham Peter LidgardInsiderSell81,025$47.16$3,821,139.00View SEC Filing  
9/5/2017Graham Peter LidgardInsiderSell75,683$40.81$3,088,623.23View SEC Filing  
9/1/2017Graham Peter LidgardInsiderSell45,775$41.49$1,899,204.75View SEC Filing  
8/17/2017Thomas D CareyDirectorBuy2,500$37.71$94,275.00View SEC Filing  
7/31/2017Jeffrey Thomas ElliottCFOSell5,846$39.41$230,390.86View SEC Filing  
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.27View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.82View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.28View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.08View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.35View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.00View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.72View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.70View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.75View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.00View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.50View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.00View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.34View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.92View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exact Sciences Corporation (NASDAQ:EXAS)
Latest Headlines for Exact Sciences Corporation (NASDAQ:EXAS)
Source:
DateHeadline
americanbankingnews.com logoExact Sciences Corporation (EXAS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 17 at 3:44 AM
nasdaq.com logoEXACT Sciences Corp. Moves Up In Market Cap Rank, Passing Mattel
www.nasdaq.com - October 16 at 6:55 PM
nasdaq.com logoIWO, EXAS, CTLT, KNX: Large Inflows Detected at ETF
www.nasdaq.com - October 13 at 4:04 PM
rttnews.com logoEXACT Sciences Corp. (EXAS) Is Losing Ground In Early Trade
www.rttnews.com - October 13 at 4:04 PM
finance.yahoo.com logoExact Sciences Stock Just Hit an All-Time High: Here's Why It Could Go Even Higher
finance.yahoo.com - October 13 at 4:04 PM
zacks.com logoPluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1%
www.zacks.com - October 11 at 8:04 PM
thestreet.com logoShort Interest Drops 32.5% For EXAS
www.thestreet.com - October 11 at 8:04 PM
bizjournals.com logoCompanies in Wisconsin, elsewhere that paid no income taxes last year
www.bizjournals.com - October 10 at 4:14 PM
finance.yahoo.com logoExact Sciences schedules third-quarter 2017 earnings call
finance.yahoo.com - October 10 at 4:14 PM
americanbankingnews.com logoCritical Analysis: Exact Sciences Corporation (EXAS) vs. Its Rivals
www.americanbankingnews.com - October 8 at 12:28 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Given Buy Rating at Robert W. Baird
www.americanbankingnews.com - October 7 at 12:24 AM
fool.com logoWhy EXACT Sciences Corporation Jumped 13.2% in September - Motley Fool
www.fool.com - October 6 at 4:15 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Exact Sciences Corporation (EXAS) Will Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - October 6 at 2:06 AM
fool.com logoWhy EXACT Sciences Corporation Jumped 13.2% in September
www.fool.com - October 5 at 7:58 PM
americanbankingnews.com logoInsider Selling: Exact Sciences Corporation (EXAS) SVP Sells 29,115 Shares of Stock
www.americanbankingnews.com - October 3 at 10:28 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 81,025 Shares
www.americanbankingnews.com - October 3 at 10:28 PM
americanbankingnews.com logoCanaccord Genuity Reaffirms "Buy" Rating for Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - October 3 at 8:40 AM
nasdaq.com logoCan Exact Sciences (EXAS) Keep the Earnings Streak Alive This Quarter? - Nasdaq
www.nasdaq.com - October 3 at 8:15 AM
finance.yahoo.com logoAtlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman
finance.yahoo.com - October 3 at 8:15 AM
finance.yahoo.com logoCan Exact Sciences (EXAS) Keep the Earnings Streak Alive This Quarter?
finance.yahoo.com - October 2 at 2:42 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 4:52 PM
americanbankingnews.com logoShort Interest in Exact Sciences Corporation (EXAS) Decreases By 11.3%
www.americanbankingnews.com - September 29 at 1:28 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Exact Sciences and Inovio Pharmaceuticals
finance.yahoo.com - September 22 at 8:18 AM
finance.yahoo.com logoWhy Exact Sciences Corporation (EXAS) Could Be A Buy
finance.yahoo.com - September 21 at 6:39 PM
americanbankingnews.com logoLeerink Swann Boosts Exact Sciences Corporation (EXAS) Price Target to $50.00
www.americanbankingnews.com - September 21 at 10:02 AM
americanbankingnews.com logo Analysts Expect Exact Sciences Corporation (EXAS) Will Post Quarterly Sales of $63.81 Million
www.americanbankingnews.com - September 19 at 9:26 AM
americanbankingnews.com logo-$0.31 EPS Expected for Exact Sciences Corporation (EXAS) This Quarter
www.americanbankingnews.com - September 17 at 8:20 AM
americanbankingnews.com logoHead to Head Survey: Matinas BioPharma Holdings (MTNB) and Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - September 15 at 9:02 PM
nasdaq.com logoIWO, CTLT, AZPN, EXAS: Large Outflows Detected at ETF - Nasdaq
www.nasdaq.com - September 12 at 7:21 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - September 10 at 12:34 AM
seekingalpha.com logoExact Sciences (EXAS) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 4:37 AM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Insider Graham Peter Lidgard Sells 75,683 Shares
www.americanbankingnews.com - September 7 at 7:22 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 6 at 4:50 PM
americanbankingnews.com logoInsider Selling: Exact Sciences Corporation (EXAS) Insider Sells 45,775 Shares of Stock
www.americanbankingnews.com - September 5 at 7:23 PM
americanbankingnews.com logo Brokerages Expect Exact Sciences Corporation (EXAS) Will Post Quarterly Sales of $63.81 Million
www.americanbankingnews.com - August 31 at 1:58 AM
nasdaq.com logoIWO, CTLT, EXAS, PRXL: Large Outflows Detected at ETF - Nasdaq ... - Nasdaq
www.nasdaq.com - August 31 at 12:52 AM
finance.yahoo.com logoExact Sciences to participate in Baird Global Healthcare Conference
finance.yahoo.com - August 30 at 7:46 PM
americanbankingnews.com logo Brokerages Anticipate Exact Sciences Corporation (EXAS) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - August 29 at 8:30 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)
finance.yahoo.com - August 29 at 6:55 PM
americanbankingnews.com logoLeerink Swann Weighs in on Exact Sciences Corporation's Q3 2017 Earnings (EXAS)
www.americanbankingnews.com - August 28 at 1:40 AM
finance.yahoo.com logo3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
finance.yahoo.com - August 25 at 8:05 PM
finance.yahoo.com logoExact Sciences: On the Way to 24 Million Tests?
finance.yahoo.com - August 24 at 7:45 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Given a $45.00 Price Target at Leerink Swann
www.americanbankingnews.com - August 24 at 1:38 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Ionis Pharmaceuticals Inc. and Exact Sciences Corporation
finance.yahoo.com - August 23 at 11:18 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Director Thomas D. Carey Acquires 2,500 Shares
www.americanbankingnews.com - August 18 at 8:32 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Exact Sciences Corp.
finance.yahoo.com - August 15 at 4:52 AM
americanbankingnews.com logo Brokerages Anticipate EXACT Sciences Co. (NASDAQ:EXAS) Will Post Quarterly Sales of $63.42 Million
www.americanbankingnews.com - August 13 at 7:40 AM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 12 at 4:44 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Short Interest Update
www.americanbankingnews.com - August 12 at 1:44 AM
americanbankingnews.com logo Analysts Expect Exact Sciences Corporation (NASDAQ:EXAS) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - August 11 at 5:11 PM

Social

Chart

Exact Sciences Corporation (EXAS) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.